Poland· PL-100017240
Epivir
A lamivudine product containing lamivudinum, registered in Poland by ViiV Healthcare BV. The same ATC class is registered in 17 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Lamivudine is registered in 17 of 19 countries.
Countries holding a registration under ATC J05AF05 (lamivudine), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 10 of them publish a price we can compare per daily dose
Lamivudine · ATC J05AF05
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of lamivudine costs, country by country.
Normalised to the WHO defined daily dose (0.3 g), the median price runs from $2.42 in France to $7.71 in Switzerland — a ×3.2 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Lamivudine · price per daily dose (0.3 g)
USD · FX 28 Sept 2026
- CH Switzerland$7.71
- IT Italy$6.75
- FR France$2.42
The record
At a glance
URPL (Poland)- Active substance
- Lamivudinum
- Manufacturer
- ViiV Healthcare BV
- Country
- Poland (PL)
- ATC code
- J05AF05
- ATC class
- Lamivudine
- Defined daily dose
- 0.3 g, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 3
- gtin05909990001637
- gtin05999540232819
- gtin05054626200486
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
207 interactions on record for lamivudine.
Graded by severity as the source publishes them — 6 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lamivudine · interactions on record
207 records
- 6 severe
- 36 moderate
- 165 info
Most severe, free to view
- BexaroteneL01XF03severe
- BexarotenL01XX25severe
- LeflunomidL04AA13severe
- TeriflunomidL04AA31severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Lamivudine in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesEPIVIRViiV Healthcare Company
- CzechiaEPIVIRViiV Healthcare BV, Amersfoort
- BelgiumDutrebis 150 mg - 300 mgMerck Sharp & Dohme
- SpainEPIVIR 150 MG COMPRIMIDOS RECUBIERTOS CON PELICULAViiv Healthcare B.V.
- FinlandEpivirViiV Healthcare BV
- FranceEPIVIR 150 mg, comprimé pelliculéVIIV HEALTHCARE UK (ROYAUME-UNI)
- NetherlandsEpivir 150 mg, tablettenViiV healthcare B.V.
- IcelandEpivirViiV Healthcare BV
Authorised across Europe · EMA
The same active substance is authorised in 12 EEA countries. Names it is sold under:
- Austria · Lamivudin Sandoz
- Cyprus · Lamivudine Normon
- Germany · Lamivudin Aurobindo, Lamivudin Mylan
- Spain · Lamivudina Accord, Lamivudina Aurovitas
- France · Lamivudine Arrow, Lamivudine Sandoz
- United Kingdom (Northern Ireland) · Lamivudine Amarox, Lamivudine Generics
- Iceland · Epivir, Lamivudine Teva
- Italy · Lamivudina Aurobindo, Lamivudina Aurobindo Italia
- Liechtenstein · Epivir, Lamivudine Teva
- Netherlands · Lamivudine Accord, Lamivudine Aurobindo
- Norway · Epivir, Lamivudine Teva
- Portugal · Lamivudina Aurobindo, Lamivudina Farmoz
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/06561f95-eb15-4b4e-9248-0bda32b8196a GET /v1/drugs/06561f95-eb15-4b4e-9248-0bda32b8196a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "150 mg",
"packaging": "05909990001637 ¦ Rpz ¦ EU/1/96/015/004 ¦ 23828\n60 tabl. w blistrze\nRpz ¦ EU/1/96/015/001 ¦ 103928\n1 butelka 60 tabl.\n¦ UR/Z/4c/155/22 - 05999540232819 ¦ UR/Z/4c/160/22 - 05054626200486 ¦ UR/Z/4c/090/23 - 05054626200486",
"substance": "Lamivudinum 150 mg",
"common_name": "Lamivudinum",
"pl_product_id": "100017240",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about lamivudine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.